EUCTR2017-004709-42-NL进行中（未招募）1 期
An open-label randomised cross-over study to evaluate the albuminuria lowering effect of dapagliflozin, exenatide and their combination in patients with type 2 diabetes - DECADE
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 17
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Type 2 diabetes
- •HbA1c = 7.5% (58 mmol/mol) and <10% (86 mmol/mol)
- •eGFR > 30 ml/min/1.73m2
- •Albumin:creatinine ratio >3.5mg/mmol and =100 mg/mmol
- •Age = 18 years
- •RAS-blockade either by ACEI or ARB, or willingness to start ACEI or ARB treatment
- •Written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 4
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 13
排除标准
- •Pregnant women and women of child-bearing potential who are not using reliable contraception
- •Cardiovascular disease
- •Uncontrolled blood pressure (office bp > 160/ 100 mmHg)
- •Active malignancy
- •History of autonomic dysfunction (e.g. history of fainting or clinically significant orthostatic hypotension)
- •Use of SGLT-2 inhibitor, GLP1-RA or DPP-4 inhibitor.
- •Lithium use
研究者
相似试验
已完成
3 期
An open-label randomised cross-over study to evaluate the albuminuria lowering effect of dapagliflozin, exenatide and their combination in patients with type 2 diabetes10012653Diabetes MellitusdiabetesNL-OMON46820Martini Ziekenhuis20
尚未招募
不适用
An open-label randomised cross-over study to evaluate the albuminuria lowering effect of dapagliflozin, exenatide and their combination in patients with type 2 diabetesDiabetes Mellitus Type 2 (DM type II), AlbuminuriaNL-OMON24855niversity Medical Center Groningen (UMCG)17
已完成
不适用
An open-label, randomized crossover study to evaluate the pharmacokinetics, bioavailability, bioequivalence, and food effect following administration of Oxybate Formulations in healthy subjects.NL-OMON41817Jazz Pharmaceuticals60
已完成
不适用
An open-label, randomized crossover study to evaluate the effect of ASP1941 on the pharmacokinetics, pharmacodynamics, safety and tolerability of glimepiride in healthy subjects and vice versa.NL-OMON34715Astellas Pharma26
已完成
不适用
A randomized, open-label, crossover study to evaluate ICS/LABA treatment versus LAMA/LABA treatment in COPD with eosinophilic inflammatioCOPDJPRN-UMIN000024905Department of Respiratory Medicine, Japanese Red Cross Ishinomaki Hospital25